阿仑单抗治疗活动性复发缓解型多发性硬化的5年随访疗效与安全性
CARE-MS II 扩展研究评估阿仑单抗在既往治疗应答不足的活动性复发缓解型多发性硬化患者中的5年疗效与安全性。多数完成核心研究的患者进入扩展期,59.8%未再接受阿仑单抗再治疗,年化复发率在扩展期各年保持低水平,无疾病活动证据比例逐年上升,脑体积丢失中位数保持低位,扩展期不良事件暴露调整发生率低于核心研究。
要点
- 阿仑单抗5年内提供持久疗效,多数患者无需持续治疗。
- 扩展期年化复发率低(第3-5年分别为0.22、0.23、0.18)。
- 甲状腺疾病在第3年达峰后下降,扩展期不良事件发生率低于核心研究。
核心结论
- 阿仑单抗在既往治疗应答不足的活动性复发缓解型多发性硬化患者中提供5年持久疗效,且无需持续治疗。
研究设计与样本
- CARE-MS II 核心研究(NCT00548405)为2年研究,阿仑单抗组接受2个疗程(基线及12个月后),随后进入扩展研究(NCT00930553),按需再治疗。
- 完成CARE-MS II的阿仑单抗治疗患者中92.9%进入扩展研究,59.8%未接受阿仑单抗再治疗。
主要发现
- 扩展期第3、4、5年年化复发率分别为0.22、0.23、0.18。
- 5年内75.1%患者无6个月确认的残疾恶化,42.9%达到6个月确认的残疾改善。
- 第3、4、5年无疾病活动证据比例分别为52.9%、54.2%、58.2%。
- 第1-5年脑体积丢失中位数分别为-0.48%、-0.22%、-0.10%、-0.19%、-0.07%。
- 扩展期不良事件暴露调整发生率低于核心研究,甲状腺疾病在第3年达峰后下降。
关键数值与推荐
- 6个月确认的残疾恶化定义为EDSS评分增加≥1分(基线EDSS=0时≥1.5分)。
- 6个月确认的残疾改善定义为EDSS评分降低≥1分(基线评分≥2.0)。
- 无疾病活动证据(NEDA)为复合终点。
临床怎么用
- 对于既往治疗应答不足的活动性复发缓解型多发性硬化患者,阿仑单抗可提供5年持久疗效且多数无需持续治疗。
- 治疗期间需监测甲状腺疾病等不良事件,扩展期不良事件发生率低于核心研究。
局限性
- 本研究提供Class III证据。
- 扩展研究为开放标签,非对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II study (NCT00548405), alemtuzumab-treated patients received 2 courses (baseline and 12 months later). Patients could enter an extension (NCT00930553), with as-needed alemtuzumab retreatment for relapse or MRI activity. Annualized relapse rate (ARR), 6-month confirmed disability worsening (CDW; ≥1-point Expanded Disability Status Scale [EDSS] score increase [≥1.5 if baseline EDSS = 0]), 6-month confirmed disability improvement (CDI; ≥1-point EDSS decrease [baseline score ≥2.0]), no evidence of disease activity (NEDA), brain volume loss (BVL), and adverse events (AEs) were assessed. RESULTS: Most alemtuzumab-treated patients (92.9%) who completed CARE-MS II entered the extension; 59.8% received no alemtuzumab retreatment. ARR was low in each extension year (years 3-5: 0.22, 0.23, 0.18). Through 5 years, 75.1% of patients were free of 6-month CDW; 42.9% achieved 6-month CDI. In years 3, 4, and 5, proportions with NEDA were 52.9%, 54.2%, and 58.2%, respectively. Median yearly BVL remained low in the extension (years 1-5: -0.48%, -0.22%, -0.10%, -0.19%, -0.07%). AE exposure-adjusted incidence rates in the extension were lower than in the core study. Thyroid disorders peaked at year 3, declining thereafter. CONCLUSIONS: Alemtuzumab provides durable efficacy through 5 years in patients with an inadequate response to prior therapy in the absence of continuous treatment. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that alemtuzumab provides efficacy and slowing of brain atrophy through 5 years.
引用
- Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017. PMID: 28835403. doi:10.1212/WNL.0000000000004354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。